An Important Step Forward in ITP: Shreeram Aradhye Shares Ianalumab Phase III Results!
Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared on LinkedIn:
”Today, at the Late-Breaking Abstract Session at the 67th American Society of Hematology Annual Meeting and Exposition, we shared positive results from a Phase III trial in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.
With a course of four once-monthly doses, our investigational therapy studied in this trial offers a promising alternative to chronic treatment.
ITP is a rare autoimmune condition where the immune system mistakenly destroys platelets, leading to prolonged bleeding, easy bruising and chronic fatigue.
This potential treatment is designed to target B cells, a key driver in ITP and other autoimmune diseases, through a dual mechanism of action.
Today’s results represent an important step forward in ITP and add to the growing body of evidence for this therapy, which is currently being studied across multiple B cell-driven conditions.
Thank you to all the patients, investigators, and teams involved in this research.”
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 13, 2025, 17:38Amaliris Guerra: Science We Do Has Real Human Stakes
-
Dec 13, 2025, 17:31Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
-
Dec 13, 2025, 17:20James Morrissey Shares the Explanation of A Literally 30 Years Worth of TF Biochemistry
-
Dec 13, 2025, 17:03Danny Hsu: Aspirin May Prevent Cancer Metastases?
-
Dec 13, 2025, 16:33Ana Cláudia de Souza: Opening Event for ÁRTEMIS-Brasil, a PROADI-SUS Project
-
Dec 13, 2025, 16:19Chandra Viswanathan on Altruism and Donating Blood
-
Dec 13, 2025, 16:09Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
-
Dec 13, 2025, 15:36Jeyaraj Pandian’s Visit to China to Support Advancement and Standardization of Stroke Care
-
Dec 12, 2025, 23:51Don’t Miss: IACH Post ASH 2025 Roundtable Debate